Literature DB >> 11841411

Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia.

Stephen B Marley1, R John Davidson, John M Goldman, Myrtle Y Gordon.   

Abstract

Combination of STI571, a tyrosine kinase inhibitor, with other drugs may be beneficial in the treatment of chronic myeloid leukaemia (CML). We measured the effects of STI571, AG490, farnesyltransferase inhibitor (FTI), interferon alpha (IFN-alpha), cytosine arabinoside (Ara-C) and all-trans retinoic acid (ATRA), singly and in combination, on clonogenic leukaemic cell proliferation. STI571, IFN-alpha and ATRA each reduced proliferation by 50-60%; AG490, FTI and Ara-C had less effect. Comparing the observed and expected (i.e. additive) effects of drug combinations showed STI571 + FTI, STI571 + AG490 and IFN-alpha + ATRA were additive; STI571 + IFN-alpha, IFN-alpha + Ara-C and STI571 + AG490 + FTI were less than additive. Thus, STI571 + FTI, STI571 + AG490 and IFN-alpha + ATRA may be better combination therapies for CML than STI571 + IFN-alpha, IFN-alpha + Ara-C or STI571 + AG490 + FTI.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11841411     DOI： 10.1046/j.1365-2141.2002.03237.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  9 in total

1.  Evolutionary dynamics of chronic myeloid leukemia.

Authors:  David Dingli; Arne Traulsen; Tom Lenaerts; Jorge M Pacheco
Journal:  Genes Cancer       Date:  2010-04

2.  ATRA promotes alpha tocopherol succinate-induced apoptosis in freshly isolated leukemic cells from chronic myeloid leukemic patients.

Authors:  Surender Kumar; Krishan Lal Khanduja; Neelam Verma; Subhash C Verma; Pramod Kumar Avti; Chander Mohan Pathak
Journal:  Mol Cell Biochem       Date:  2007-09-15       Impact factor: 3.396

3.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Authors:  Tom Lenaerts; Jorge M Pacheco; Arne Traulsen; David Dingli
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

4.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

Authors:  M Golam Mohi; Christina Boulton; Ting-Lei Gu; David W Sternberg; Donna Neuberg; James D Griffin; D Gary Gilliland; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

5.  Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.

Authors:  Shinya Kimura; Junya Kuroda; Hidekazu Segawa; Kiyoshi Sato; Masaki Nogawa; Takeshi Yuasa; Oliver G Ottmann; Taira Maekawa
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 6.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

7.  Molecular mechanisms of the combination of retinoid and interferon-gamma for inducing differentiation and increasing apoptosis in human glioblastoma T98G and U87MG cells.

Authors:  Arabinda Das; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2008-03-27       Impact factor: 3.996

8.  Differentiation decreased telomerase activity in rat glioblastoma C6 cells and increased sensitivity to IFN-gamma and taxol for apoptosis.

Authors:  Arabinda Das; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2007-08-13       Impact factor: 3.996

9.  A stochastic model of oncogene expression and the relevance of this model to cancer therapy.

Authors:  Francis D Alfano
Journal:  Theor Biol Med Model       Date:  2006-01-31       Impact factor: 2.432
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.